Literature DB >> 25266042

Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

Rintaro Ono1, Daisuke Hasegawa, Shinsuke Hirabayashi, Takahiro Kamiya, Kenichi Yoshida, Satoko Yonekawa, Chitose Ogawa, Ryota Hosoya, Tsutomu Toki, Kiminori Terui, Etsuro Ito, Atsushi Manabe.   

Abstract

UNLABELLED: GATA1 mutations are found almost exclusively in children with myeloid proliferations related to Down syndrome (DS). Here, we report two phenotypically and cytogenetically normal children with acute megakaryoblastic leukemia (AMKL) whose blasts had both acquired trisomy 21 and GATA1 mutation. Patient 1 was diagnosed with transient abnormal myelopoiesis in the neonatal period. Following spontaneous improvement of the disease, leukemic blasts increased 7 months later. He received less intensive chemotherapy, and he is now 6 years old in complete remission. Patient 2 was diagnosed with AMKL at the age of 18 months. Although he received intensive chemotherapy and a cord blood transplantation, he died without gaining remission. In both cases, trisomy 21 and GATA1 mutation were detected only in leukemic blasts, but not in germline samples. Based on a literature review, we identified reports describing 14 non-DS AMKL with GATA1 mutation and acquired trisomy 21. Of those, 12 cases were diagnosed during the neonatal period, whereas the remaining 2 cases were diagnosed at the age of 22 and 31 months, respectively.
CONCLUSION: These cases suggest that GATA1 mutation may cooperate with the additional chromosome 21 in developing myeloid proliferations even in non-DS patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25266042     DOI: 10.1007/s00431-014-2430-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  27 in total

1.  Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.

Authors:  Hiroto Inaba; Margherita Londero; Scott H Maurer; Mihaela Onciu; Yubin Ge; Jeffrey W Taub; Jeffrey E Rubnitz; Susana C Raimondi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

2.  GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.

Authors:  Emily Carpenter; Veronica Valverde-Garduno; Alex Sternberg; Chris Mitchell; Irene Roberts; Paresh Vyas; Ajay Vora
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

Review 3.  Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21.

Authors:  Alvin Zipursky
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

4.  Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.

Authors:  Thomas Cushing; Carol L Clericuzio; Carla S Wilson; Jeffrey W Taub; Yubin Ge; Kaaren K Reichard; Stuart S Winter
Journal:  J Pediatr       Date:  2006-05       Impact factor: 4.406

5.  Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation.

Authors:  Isis Quezado Magalhães; Alessandra Splendore; Mariana Emerenciano; Mara Santos Córdoba; Jose Carlos Córdoba; Paula Azevedo Allemand; Iris Ferrari; Maria S Pombo-de-Oliveira
Journal:  J Pediatr Hematol Oncol       Date:  2005-01       Impact factor: 1.289

6.  Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.

Authors:  Kazuko Kudo; Asahito Hama; Seiji Kojima; Ruriko Ishii; Akira Morimoto; Fumio Bessho; Shosuke Sunami; Naoyuki Kobayashi; Akitoshi Kinoshita; Yuri Okimoto; Akio Tawa; Ichiro Tsukimoto
Journal:  Int J Hematol       Date:  2010-03-18       Impact factor: 2.490

7.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 8.  Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.

Authors:  Claudio Sandoval; Sharon R Pine; Qianxu Guo; Sudha Sastry; Julian Stewart; David Kronn; Somasundaram Jayabose
Journal:  Pediatr Blood Cancer       Date:  2005-01       Impact factor: 3.167

9.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.

Authors:  Gita V Massey; Alvin Zipursky; Myron N Chang; John J Doyle; Suhail Nasim; Jeffrey W Taub; Yaddanapudi Ravindranath; Gary Dahl; Howard J Weinstein
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

10.  Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins.

Authors:  Batia Stark; Marta Jeison; Claude Preudhomme; Pierre Fenaux; Shifra Ash; Yifat Korek; Jerry Stein; Rina Zaizov; Issac Yaniv
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

View more
  7 in total

1.  Donor cell-derived transient abnormal myelopoiesis as a specific complication of umbilical cord blood transplantation.

Authors:  N Hiramoto; J Takeda; K Yoshida; Y Ono; S Yoshioka; N Yamauchi; A Fujimoto; H Maruoka; Y Shiraishi; H Tanaka; K Chiba; Y Imai; S Miyano; S Ogawa; T Ishikawa
Journal:  Bone Marrow Transplant       Date:  2017-10-09       Impact factor: 5.483

2.  Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.

Authors:  Henrik Hasle; Ronald M Kline; Eigil Kjeldsen; Nik F Nik-Abdul-Rashid; Deepa Bhojwani; Jeffrey M Verboon; Stephanie P DiTroia; Katherine R Chao; Klas Raaschou-Jensen; Josefine Palle; C Michel Zwaan; Charlotte Guldborg Nyvold; Vijay G Sankaran; Alan B Cantor
Journal:  Blood       Date:  2022-05-26       Impact factor: 25.476

3.  Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study.

Authors:  Jasmijn D E de Rooij; Riccardo Masetti; Marry M van den Heuvel-Eibrink; Jean-Michel Cayuela; Jan Trka; Dirk Reinhardt; Mareike Rasche; Edwin Sonneveld; Todd A Alonzo; Maarten Fornerod; Martin Zimmermann; Martina Pigazzi; Rob Pieters; Soheil Meshinchi; C Michel Zwaan; Franco Locatelli
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

4.  Sometimes it is better to wait: First Italian case of a newborn with transient abnormal myelopoiesis and a favorable prognosis.

Authors:  Guglielmo Salvatori; Silvia Foligno; Pietro Sirleto; Silvia Genovese; Serena Russo; Valentina Coletti; Andrea Dotta; Matteo Luciani
Journal:  Oncol Lett       Date:  2016-11-21       Impact factor: 2.967

Review 5.  Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.

Authors:  Anouchka P Laurent; Rishi S Kotecha; Sébastien Malinge
Journal:  Leukemia       Date:  2020-05-20       Impact factor: 11.528

Review 6.  Advances in molecular characterization of myeloid proliferations associated with Down syndrome.

Authors:  Jixia Li; Maggie L Kalev-Zylinska
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

7.  Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia.

Authors:  Haixiao Qi; Yan Mao; Qian Cao; Xingzhen Sun; Wenxia Kuai; Junhong Song; Li Ma; Ze Hong; Jian Hu; Guoping Zhou
Journal:  Med Sci Monit       Date:  2020-06-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.